Drawing for PROBIODRUG

USPTO serial 76471856

PROBIODRUG

Reviewed by CopyMark Law Group

Reg. 2833852Status 710
Filing date
Status date
Registration date
Apr 20, 2004
Examiner
SMITH, BRIDGETT G
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PROBIODRUG?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David Toren

KATRIN LEWERTOFF SIDLEY AUSTIN LLP787 7TH AVENEW YORK, NY 10019UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical preparations for the use in the manufacture of pharmaceuticals for the treatment of type 2 diabetes, impaired glucose tolerance, glucosuria, and disturbances of signal action at the cells of the islets of Langerhans and insulin sensitivity in the peripheral tissue in the postprandial phase of mammals, insulin resistance, metabolic acidosis, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus, diabetes mellitus type 1, lipid disorders, hyperlipidemia, metabolism-related hypertension and cardiovascular sequelae caused by hypertension in mammals, atherosclerosis and its sequelae, inflammatory bowel disease, namely, Crohn's disease and ulcerative colitis, pancreatitis, tumor metastasis, benign prostatic hypertrophy, gingivitis, osteoporosis, for the prophylaxis or treatment of skin diseases and diseases of the mucosae, autoimmune diseases and inflammatory conditions, and for the prophylaxis or treatment of psychosomatic, neuropsychiatric and depressive illness, and neurodegenerative diseases namely anxiety, depression, sleep disorders, chronic fatigue, schizophrenia, epilepsy, nutritional disorders, spasm, and chronic pain, multiple sclerosis, Alzheimer's disease, Down Syndrome, and for use in the manufacture of contraceptive drugs for scientific, medical and biological purposes, diagnostic preparations and reagents for use in scientific and medical researchSECTION 8 - CANCELLED—
005Pharmaceutical preparations for the treatment of non-insulin dependent diabetes mellitus (type 2), impaired glucose tolerance, glucosuria, and disturbances of signal action at the cells of the islets of Langerhans and insulin sensitivity in the peripheral tissue in the postprandial phase of mammals, insulin resistance, metabolic acidosis, diabetic neuropathy and nephropathy and of sequelae caused by diabetes mellitus, diabetes mellitus type 1, lipid disorders, hyperlipidemia, metabolism-related hypertension and cardiovascular sequelae caused by hypertension in mammals; pharmaceutical preparations for the treatment of atherosclerosis and its sequelae, inflammatory bowel disease, namely, Crohn's disease and ulcerative colitis, pancreatitis, tumor metastasis, benign prostatic hypertrophy, gingivitis, osteoporosis; pharmaceutical preparations for the prophylaxis or treatment of skin diseases and diseases of the mucosae, autoimmune diseases and inflammatory conditions, and for the prophylaxis or treatment of psychosomatic, neuropsychiatric and depressive illness, and neurodegenerative diseases namely, anxiety, depression, sleep disorders, chronic fatigue, schizophrenia, epilepsy, nutritional disorders, spasm, and chronic pain, multiple sclerosis, Alzheimer's disease; Veterinary preparations for the treatment of metabolic diseases, cancerous diseases, psychosomatic, neuropsychiatric, depressive and neurodegenerative diseases in livestock and domestic animals; All purpose disinfectants, diagnostic reagents for clinical or medical use; Dietary supplements, food for enteral feeding; Agrochemicals, namely fungicides, herbicides and insecticides for agricultural and domestic useSECTION 8 - CANCELLED—
010surgical, medical, dental and veterinary instruments and apparatus, namely electronic monitors, recorders and analyzers for blood pressure, blood analysis, blood glucose, insulin in the blood, pH MonitorsSECTION 8 - CANCELLED—
041educational services, namely conducting classes, seminars, conferences and workshops in the field of human medicine, veterinary medicine, human nutrition, pet nutrition and agricultureSECTION 8 - CANCELLED—
042Chemist, physicist, microbiologist, biologist and Chemical, biological and medical research in the field of drugs and genetic engineeringSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 26, 2010C8..CANCELLED SEC. 8 (6-YR)—
Jul 6, 2006TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 20, 2004R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 27, 2004PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 7, 2004NPUBNOTICE OF PUBLICATION—
Nov 25, 20031.BDSec. 1(B) CLAIM DELETED—
Nov 14, 2003TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 13, 2003MAILPAPER RECEIVED—
Oct 27, 2003CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 23, 2003CNEAEXAMINERS AMENDMENT MAILED—
Jul 2, 2003CFITCASE FILE IN TICRS—
Jun 16, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 16, 2003MAILPAPER RECEIVED—
Mar 24, 2003CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 12, 2003DOCKASSIGNED TO EXAMINER—
Jan 31, 2003MAILPAPER RECEIVED—

Frequently asked questions

Related guidance